Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment for Stress Urinary Incontinence.
Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment for Stress Urinary Incontinence: a Prospective Observational Cohort Study
This prospective single-center observational cohort study will assess changes in urethrovesical junction (UVJ) mobility and urethral morphology after vaginal Er:YAG laser treatment in 40 adult women with pure stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence.
Participants will independently choose self-paid laser treatment as routine clinical care before being offered study participation. Treatment comprises three sessions at 4-6-week intervals. Standardized 4D transperineal ultrasound and clinical assessments will be performed at baseline and 1, 3, and 6 months after the final session.
The primary outcome is change in craniocaudal UVJ mobility, measured in millimeters, from baseline to 1 month after the final session. Secondary outcomes include UVJ mobility at 3 and 6 months, UVJ position, mid-urethral morphology, patient-reported outcomes, cough stress test results, adverse events, and initiation of additional SUI treatment. Exploratory analyses will assess associations between ultrasound changes and clinical outcomes.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Jan Dvorak, M.D. Ph.D.
- 電話番号：00420224967577
- メール：jan.dvorak2@vfn.cz
研究場所
-
-
-
Prague、チェコ、142 00
- 募集
- General University Hospital in Prague
-
コンタクト：
- Jan Dvorak, M.D. Ph.D.
- 電話番号：00420224967425
- メール：jan.dvorak2@vfn.cz
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adult female patients attending the participating outpatient clinical site who have independently elected to undergo self-paid vaginal laser treatment as routine clinical care for pure stress urinary incontinence or stress-predominant mixed urinary incontinence. Patients must have urodynamically demonstrated stress urinary incontinence without detrusor overactivity. Patients will be screened consecutively during the recruitment period, and those meeting the eligibility criteria will be invited to participate.
説明
Inclusion Criteria:
- Female sex.
- Age 18 years or older.
- Pure stress urinary incontinence or stress-predominant mixed urinary incontinence. In women with mixed urinary incontinence, the stress component must be the dominant and most bothersome symptom.
- Urodynamically demonstrated stress urinary incontinence.
- Absence of detrusor overactivity on urodynamic testing.
- Independent decision to undergo self-paid vaginal laser treatment as routine clinical care, made before the offer of study participation.
- Ability to complete the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF).
- Ability to perform a technically acceptable Valsalva maneuver.
- Willingness to attend the scheduled follow-up visits.
- Written informed consent to study participation.
Exclusion Criteria:
- Predominant overactive bladder or predominant urgency urinary incontinence.
- Previous surgery for stress urinary incontinence.
- Previous vaginal laser treatment.
- Previous pelvic organ prolapse surgery.
- Pelvic Organ Prolapse Quantification (POP-Q) stage II or greater in any compartment.
- Current pessary use at enrollment.
- Active pelvic floor physiotherapy at enrollment.
- Previous pelvic radiotherapy.
- Pregnancy.
- Unexplained genital bleeding.
- Pelvic malignancy.
- Any other contraindication to vaginal laser treatment.
- Active urinary tract or vaginal infection. Enrollment and laser treatment will be deferred until the infection has resolved.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：COHORT
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Stress urinary incontinence
A prospective cohort of 40 women aged 18 years or older with urodynamically demonstrated pure stress urinary incontinence or stress-predominant mixed urinary incontinence, without detrusor overactivity. Participants independently choose vaginal laser treatment as routine clinical care before being offered study enrollment. Treatment comprises three non-ablative Er laser sessions (Fotona SP Dynamis Pro; IncontiLase, SMOOTH mode) at 4-6-week intervals. Standardized 4D transperineal ultrasound and clinical assessments are performed before the first session and at 1, 3, and 6 months after the final session. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From in Craniocaudal Urethrovesical Junction Mobility
時間枠：Baseline (before the first laser session) and 1 month after the final laser session.
|
Within-participant change in craniocaudal urethrovesical junction (UVJ) mobility, measured in millimeters using standardized 4D transperineal ultrasound. UVJ position is measured relative to a horizontal reference line through the posteroinferior margin of the pubic symphysis, with cranial positions coded as negative and caudal positions as positive. Mobility is calculated as UVJ position during maximal Valsalva minus UVJ position at rest. Change is calculated as mobility at 1 month after the final laser session minus baseline mobility. Negative values indicate reduced mobility. |
Baseline (before the first laser session) and 1 month after the final laser session.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in Craniocaudal Urethrovesical Junction Mobility at 3 and 6 Months After the Final Laser Session
時間枠：Baseline (before the first laser session) and 3 and 6 months after the final laser session.
|
Within-participant change in craniocaudal urethrovesical junction (UVJ) mobility, measured in millimeters using standardized 4D transperineal ultrasound. Mobility is calculated as UVJ position during maximal Valsalva minus UVJ position at rest. Change is follow-up mobility minus baseline mobility, assessed separately at 3 and 6 months. Negative values indicate reduced mobility. |
Baseline (before the first laser session) and 3 and 6 months after the final laser session.
|
|
Change From Baseline in Urethrovesical Junction Position at Rest
時間枠：Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
Change in craniocaudal urethrovesical junction position at rest, measured in millimeters using 4D transperineal ultrasound relative to a horizontal line through the posteroinferior margin of the pubic symphysis. Cranial positions are negative and caudal positions positive. Change is follow-up position minus baseline position. |
Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
|
Change From Baseline in Mid-Urethral Hypoechoic Cross-Sectional Area at Rest
時間枠：Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
Change in the cross-sectional area of the hypoechoic mid-urethral region at rest, measured in square millimeters by manual tracing on 4D transperineal ultrasound. The measurement plane is perpendicular to the urethral axis at 50% of sonographic urethral length. Change is follow-up area minus baseline area. |
Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
|
Change From Baseline in ICIQ-UI SF Total Score
時間枠：Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
Change in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) total score. Scores range from 0 to 21, with higher scores indicating greater urinary incontinence severity and impact. Change is follow-up score minus baseline score; negative values indicate improvement. |
Baseline (before the first laser session) and 1, 3, and 6 months after the final laser session.
|
|
Patient Global Impression of Improvement Category
時間枠：1, 3, and 6 months after the final laser session
|
Distribution of responses on the Patient Global Impression of Improvement (PGI-I), a 7-point scale assessing perceived change in urinary incontinence compared with the pretreatment condition. Scores range from 1 (very much better) to 7 (very much worse), with 4 indicating no change. Lower scores indicate greater perceived improvement. |
1, 3, and 6 months after the final laser session
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 6/5/2025
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。